Opko Health Inc. (NASDAQ:OPK) announced the appointment of health care executive as well as medical doctor Jon. R Cohen as the executive chairman of BioReference Laboratories.
OPKO Health Strengthening the “House”
OPKO Health is a multinational pharmaceutical as well as a diagnostic firm with its BioReference Laboratories being the 3rd largest clinical lab in the US. In 2006, it acquired GeneDx (a genetic testing company which develops various tests for the rare disorders for about $17 million.
The appointment of Cohen shows the focus within Opko Health to propel their objectives forward into the New Year 2019. Besides, they also promoted Geoff Monk to President of BioReference who is to report directly to Dr. Cohen.
The appointments may have come just at the right time as it’s merely at the begging of the year and the appointees have the whole time in the world to provide the right directions to the company with their capable and fantastic track record.
What Will They Bring to the Table?
Being appointed to a senior official position means Dr. Cohen and Mr. Monk tick the boxes to hold onto those positions. Dr. Cohen brings forth over 30 years of experience healthcare as a seasoned strategic individual. He has a decorated record in expanding the existing business as well as developing new ventures.
Also, for almost a decade he served as a senior executive at Quest Diagnostics, managing director health industries services, Price water house Coopers as well as chief medical officer North Shore-Long Island Jewish Health System.
Monk joined BioReference in 2018 as general manager, but within a short period, he has been a superb executive earning respect as well as the admiration of his colleagues according to Phillip Frost, M.D., Chairman and Executive Officer of Opko Health. In addition, Frost spoke highly of Cohen’s commercial success and stated that the future of Opko’s diagnostic business is in safer hands.
For the better success of any firm, the leaders have to be sound mind and experience is a catalyst. For now, Opko has been placed in capable hands and apparently they have a bright future to take.